# Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS

> **NCT05823480** · PHASE1 · WITHDRAWN · sponsor: **City of Hope Medical Center**

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndrome

## Interventions

- **PROCEDURE:** Allogeneic Hematopoietic Stem Cell Transplantation
- **DRUG:** Azacitidine
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspirate
- **PROCEDURE:** Bone Marrow Biopsy
- **PROCEDURE:** Echocardiography
- **BIOLOGICAL:** Magrolimab
- **PROCEDURE:** Multigated Acquisition Scan
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT05823480
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-10-09
- **Primary completion:** 2026-02-14
- **Final completion:** 2026-02-14
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawn -ctms
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05823480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05823480, "Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT05823480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*